Abstract
BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety.
METHODS: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m 2 and ≥60 mL/min per 1·73 m 2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850.
FINDINGS: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups.
INTERPRETATION: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan.
FUNDING: Travere Therapeutics.
| Original language | English |
|---|---|
| Pages (from-to) | 1584-1594 |
| Number of pages | 11 |
| Journal | The Lancet |
| Volume | 401 |
| Issue number | 10388 |
| DOIs | |
| Publication status | Published - 13 May 2023 |
Keywords
- Adolescent
- Adult
- Creatinine/urine
- Double-Blind Method
- Glomerulonephritis, IGA/drug therapy
- Humans
- Irbesartan/therapeutic use
- Proteinuria/drug therapy
- Treatment Outcome
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet, Vol. 401, No. 10388, 13.05.2023, p. 1584-1594.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
AU - Heerspink, Hiddo J.L.
AU - Radhakrishnan, Jai
AU - Alpers, Charles E.
AU - Barratt, Jonathan
AU - Bieler, Stewart
AU - Diva, Ulysses
AU - Inrig, Jula
AU - Komers, Radko
AU - Mercer, Alex
AU - Noronha, Irene L.
AU - Rheault, Michelle N.
AU - Rote, William
AU - Rovin, Brad
AU - Trachtman, Howard
AU - Trimarchi, Hernán
AU - Wong, Muh Geot
AU - Perkovic, Vlado
AU - Alarmartine, Eric
AU - Chae, Dong Wan
AU - Del Vecchio, Lucia
AU - Floege, Jurgen
AU - Hwang, Shang Jyh
AU - Jelakovic, Bojan
AU - Maes, Bart
AU - Malecki, Robert
AU - Miglinas, Marius
AU - Nolasco, Fernando Eduardo Barbosa
AU - Praga, Manual
AU - Rabindranath, Kannaiyan
AU - Rosenberg, Mai
AU - Tang, Sydney Chi Wai
AU - Tesar, Vladmir
AU - Bose, Bhadran
AU - Gangadharan, Muralikrishna
AU - McDonald, Stephen
AU - Peh, Chen
AU - Jahan, Sadia
AU - Yeap, Chii
AU - Clayton, Philip
AU - Irish, Georgina
AU - Thyagarajan, Nikhil
AU - Hollett, Peter
AU - Krishnasamy, Rathika
AU - Carroll, Robert
AU - Jesudason, Shilpanjali
AU - Crail, Susan
AU - Coates, Toby
AU - Waugh, Jane
AU - Noble, Euan
AU - Mahadevan, Kumaradevan
AU - Campbell, Victoria
AU - Salehi, Tania
AU - Lim, Wai
AU - Boudville, Neil
AU - Chakera, Aron
AU - Chan, Doris
AU - Krishnan, Anoushka
AU - Eqbal, Yusuf
AU - Gillies, Alastair
AU - Vilayur, Eswari
AU - Maung Myint, Thida Maung
AU - Gray, Nicholas
AU - Cheetham, Melissa
AU - Pollock, Carol
AU - Cooper, Bruce
AU - Mather, Amanda
AU - Roxburgh, Sarah
AU - Shen, Yvonne
AU - Stangenberg, Stefanie
AU - Siriwardana, Amanda
AU - O'Lone, Emma
AU - Wan, Susan
AU - Neuen, Brendon
AU - Tsun Kit Ha, Jeffrey
AU - Kim, Dana
AU - Heath, Lauren
AU - Jain, Arunima
AU - Phua, Elaine
AU - Li, Yan
AU - Gallagher, Martin
AU - Jardine, Meg
AU - Ritchie, Angus
AU - Razavian, Mona
AU - Foote, Celine
AU - Wyndham, Roger
AU - Sen, Shaundeep
AU - Endre, Zoltan
AU - Erlich, Jonathan
AU - Fernando, Mangalee
AU - Yong, Kenneth
AU - Luxton, Grant
AU - Kotwal, Sradha
AU - Roger, Simon
AU - Wijeratne, Vidu
AU - Packham, David
AU - Fraser, Ian
AU - Vandewiele, Bert
AU - Laute, Margo
AU - Lemahieu, Wim
AU - Jamar, Sofie
AU - Ombelet, Sara
AU - Meeus, Gert
AU - Decupere, Marc
AU - Schockaert, Olivier
AU - Doubel, Peter
AU - Viaene, Liesbeth
AU - Radermacher, Luc
AU - Masset, Catherine
AU - Moonen, Martial
AU - Firre, Eric
AU - Milicevic, Martina
AU - Warling, Xavier
AU - Vanacker, An
AU - Malfait, Thomas
AU - Durlen, Ivan
AU - Horvatic, Ivica
AU - Savuk, Ana
AU - Gellineo, Lana
AU - Karanovic, Sandra
AU - Dika, Zivka
AU - Plavljanic, Djuro
AU - Mikacic, Ivana
AU - Trajbar Kentric, Dubravka
AU - Barisic, Dunja
AU - Stankovic, Marija
AU - Majstorovic Barac, Karolina
AU - Kruljac, Ivan
AU - Pavlovic, Drasko
AU - Drinkovic, Martin
AU - Prkacin, Ingrid
AU - Barbic, Jerko
AU - Sitas, Zvonimir
AU - Vujcic, Dunja
AU - Rychlik, Ivan
AU - Benesova, Anna
AU - Drinovska, Klara
AU - Kratka, Karolina
AU - Maixnerova, Dita
AU - Ilmoja, Madis
AU - Unt, Kristin
AU - Lilienthal, Kadri
AU - Auerbach, Asta
AU - Leis, Liisi
AU - Piel, Julia
AU - Adoberg, Annika
AU - Kolvald, Kulli
AU - Veermae, Kristi
AU - Telling, Kadri
AU - Seppet, Elviira
AU - Uhlinova, Jana
AU - Zaoui, Philippe
AU - Carron, Pierre Louis
AU - Masson, Ingrid
AU - Dinic, Miriana
AU - Thibaudin, Damien
AU - Broyet, Christian
AU - Maillard, Nicolas
AU - Mohey, Hesham
AU - Mariat, Christophe
AU - Claisse, Guillaume
AU - Alamartine, Eric
AU - Dussol, Bertrand
AU - Burtey, Stephane
AU - Chiche-Jourde, Noemie
AU - Serre, Jean Emmanuel
AU - Jeantet, Guillaume
AU - Chenine, Leila
AU - Blanchard, Anne
AU - Roueff, Stephane
AU - Thervet, Eric
AU - Fouassier, David
AU - Buffet, Alexandre
AU - Livrozet, Marine
AU - Gaisset, Roxane
AU - Karras, Alexandre
AU - Heng, Anne Elisabeth
AU - Garrouste, Cyril
AU - Philipponnet, Carole
AU - Nicolo, Clementine
AU - Atenza, Alba
AU - Lanaret, Camille
AU - Greze, Clarisse
AU - Mayet, Valentin
AU - Dumond, Clement
AU - Delmas, Yahsou
AU - Combe, Christian
AU - Rigothier, Claire
AU - Burguet, Laure
AU - Labat, Aurore
AU - Mucha, Simon
AU - de Précigout, Valérie
AU - Weinreich, Thomas
AU - Reichel, Helmut
AU - Draganova, Diliana
AU - Wolf, Lothar
AU - Hohenstein, Bernd
AU - Heinrichs, Sven
AU - Kulka, Simone
AU - Sat, Sebahat
AU - Weiland, Lea
AU - Krueger, Thilo
AU - Wolf, Gunter
AU - Kettner, Christiane
AU - Schlosser, Mandy
AU - Herfurth, Johann Konstantin
AU - Koch, Annegret
AU - Busch, Martin
AU - Werth, Stephan Christian
AU - Nitschke, Martin
AU - Cakiroglu, Figen
AU - Sarnow, Franziska
AU - Schulz, Lisa
AU - Weiner, Stefan
AU - Wirtz, Nikolaus
AU - Koester, Eric
AU - Moeller, Marcus
AU - Stamellou, Eleni
AU - Sanden, Silja
AU - Schmidt-Guertler, Hans
AU - Bernhardt, Wanja
AU - Patecki, Margret
AU - Schlieper, Georg
AU - Schulte, Kevin
AU - Girardet, Annette
AU - Kunzendorf, Ulrich
AU - Kwan, Lorraine Pui Yuen
AU - Mok, Maggie Ming Yee
AU - Chan, Gary Chi Wang
AU - Ma, Mingyao
AU - Lie, Davina Ngoi Wah
AU - Chan, Anthony Ting Pong
AU - Szeto, Cheuk Chun
AU - Ng, Kit Chung Jack
AU - Cheung, Siu Fai
AU - Yue, Tak Tai Andrew
AU - Fung, Ka Shun Samuel
AU - Tang, Hon
AU - Yim, Ka Fai
AU - Law, Wai Ping
AU - Wong, Yick Hei
AU - Lam, Chi Kwan Darwin
AU - Wong, Sze Ho Sunny
AU - Marcantoni, Carmelita
AU - Aliotta, Roberta
AU - Deodato, Francesca
AU - Patella, Gemma
AU - Comi, Nicolino
AU - Vita, Caterina
AU - Carullo, Nazareno
AU - Bolignano, Davide
AU - Musolino, Michela
AU - Trillini, Matias
AU - Perico, Norberto
AU - Remuzzi, Giuseppe
AU - Daina, Erica
AU - Biancone, Luigi
AU - Colla, Loredana
AU - Burdese, Manuel
AU - Cogno, Chiara
AU - Boaglio, Elena
AU - Abbasciano, Isabella
AU - Zizzi, Carlotta Federica
AU - Randone, Paolo
AU - Napodano, Pietro
AU - Ricchiuto, Anna
AU - Cassia, Matthias
AU - Accarino, Simone
AU - Cozzolino, Mario
AU - Baccaro, Rocco
AU - Costanzi, Stefano
AU - Di Maio, Federica
AU - Arena, Maria
AU - Urciuolo, Federica
AU - Vigano, Sara
AU - Cavalli, Andrea
AU - Limardo, Monica
AU - Bordoli, Monica
AU - Ponti, Serena
AU - Longhi, Selena
AU - Solazzo, Andrea
AU - Giaroni, Francesco
AU - Donati, Gabriele
AU - Torreggiani, Massimo
AU - Catucci, Davide
AU - Colucci, Marco
AU - Esposito, Vittoria
AU - Esposito, Ciro
AU - Gesualdo, Loreto
AU - Capaccio, Flavia
AU - Diletta Stea, Emma
AU - Sivo, Carmen
AU - Annese, Francesca
AU - Papadia, Federica
AU - Messa, Piergiorgio
AU - Belingheri, Mirco
AU - Passerini, Patrizia
AU - Malvica, Silvia
AU - Vickiene, Alvita
AU - Zakauskiene, Urte
AU - Asakiene, Egle
AU - Bumblyte', Inga Arune
AU - Stankuviene, Asta
AU - Santockiene, Lina
AU - Hayat, Ashik
AU - Williams, Allister
AU - Sizeland, Peter
AU - Tan, Eddie
AU - Waters, Gerald
AU - Chan, Lai Wan
AU - Henderson, Andrew
AU - Turnbull, Angus
AU - McNally, Andrew
AU - Reynolds, Annie
AU - Pilmore, Helen
AU - Dittmer, Ian
AU - Manley, Paul
AU - Stallworthy, Elizabeth
AU - Goh, Tze
AU - Semple, David
AU - Collins, Michael
AU - Curry, Elizabeth
AU - Ahmed, Jafar
AU - Nguyen, Thu
AU - Winiarska, Agata
AU - Zbrzezniak, Justyna
AU - Stompor, Tomasz
AU - Krajewska, Magdalena
AU - Augustyniak-Bartosik, Hanna
AU - Zielinska, Dorota
AU - Jander, Anna
AU - Stanczyk, Malgorzata
AU - Tkaczyk, Marcin
AU - Miarka, Przemyslaw
AU - Aksamit, Dariusz
AU - Jaskowski, Piotr
AU - Sulowicz, Wladyslaw
AU - Cieniawski, Dominik
AU - Gontarek-Kacprzak, Julita
AU - Felicjanczuk, Elzbieta
AU - Kwella, Norbert
AU - Kwella, Bogna
AU - Satora, Ewa
AU - Fernandes, João Carlos
AU - Gomes, Ana Marta
AU - Reis, Marina
AU - Lopes, Daniela
AU - Almeida, Catarina
AU - Sá, Helena
AU - Figueiredo, Ana Carolina
AU - Pardinhas, Clara
AU - Almeida, Edgar
AU - Raimundo, Mario
AU - Cortesão Costa, Ana
AU - Falcao Goncalves, Luis Pedro
AU - Fernandes, Sara
AU - Silva, Sónia
AU - Teixeira, Catarina
AU - Fernandes, Adriana
AU - Nolasco, Fernando
AU - Alves, Patricia
AU - Gois, Mario
AU - Fonseca, Nuno
AU - Messias, Ana
AU - Menezes, Maria
AU - Cardoso, Filipa
AU - Sousa, Helena
AU - Marques, Joana
AU - Barata, Rui
AU - Lopes, Jose Antonio
AU - Jorge, Sofia
AU - Gameiro, Joana
AU - de Almeida Agapito Fonseca, Jose Nuno
AU - Goncalves, Sara
AU - Farinha, Ana
AU - Valerio Santos, Patricia
AU - Natario, Ana
AU - de Jesus Barreto, Jose Carlos
AU - Abrantes, Catarina
AU - Quadrado Soares, Elsa Sofia
AU - Soares Felgueiras, Joana de Sousa
AU - Cunha, Liliana
AU - Parreira, Lucia
AU - Furtado, Teresa
AU - Vaz, Alvaro
AU - Oh, Kook Hwan
AU - Lee, Hajeong
AU - Joong Kim, Se
AU - Jeong, Jong Cheol
AU - Hoon Kim, Yeong
AU - Kim, Yunmi
AU - Park, Hyeong Cheon
AU - Choi, Hoon Young
AU - Wook Kim, Hyung
AU - Lee, Moon Hyoung
AU - Yoon, Songuk
AU - Lee, Kyu Beck
AU - Hyun, Young Youl
AU - Yoo, Tae Hyun
AU - Han, Seung Hyeok
AU - Park, Jung Tak
AU - Kim, Sunggyun
AU - Song, Young Rim
AU - Kim, Jwa Kyung
AU - Lee, Hyung seok
AU - Joo, Narae
AU - Lee, Jung Eun
AU - Ryoun Jang, Hye
AU - Jeon, Junseok
AU - Chung, Wookyung
AU - Lee, Hyun Hee
AU - Chang, Jae Hyun
AU - Chun, Ka Yeong
AU - Jung, Ji Yong
AU - Ro, Han
AU - Kim, Aejin
AU - Jo, Sang Kyung
AU - Yang, Jihyun
AU - Kim, Myung Gyu
AU - Oh, Se Won
AU - Martinez Villanueva, Caridad
AU - Gimeno, Ana Vilar
AU - Andres Useche Bonilla, Gustavo
AU - Tamarit, Esther
AU - Galan Serrano, Antonio
AU - Verde Moreno, Eduardo
AU - Fernandez, Jose Luño
AU - Goicoechea Diezhandino, Maria Angeles
AU - Verdalles Guzman, Ursula
AU - de Jose, Ana Perez
AU - Ortiz Arduan, Alberto
AU - Pérez Gómez, María Vanessa
AU - Martín Cleary, Catalina
AU - Prado, Raul Fernandez
AU - Goma, Elena
AU - Ballarin, Jose
AU - Encarnacion, Montserrat Diaz
AU - Da Silva Santos, Iara
AU - Marco Rusinol, Helena
AU - Furlano, Monica
AU - Arias, Carlos
AU - Barrios, Clara
AU - Garcia, Eva Rodriguez
AU - Sierra Ochoa, Adriana
AU - Vizcaino Castillo, Belen
AU - Pantoja Perez, Jonay
AU - Gonzalez Moya, Mercedes
AU - Sargsyan, Mari
AU - Calatayud Aristoy, Emma
AU - Bernabeu, Ana Avila
AU - Perez Lluna, Leticia
AU - Malek Marin, Tamara
AU - Antonia Munar Vila, Maria
AU - Bobadilla Rico, Ivon Maritza
AU - Allende Burgos, Natalia
AU - Gutierrez Martinez, Eduardo
AU - Gutierrez Solis, Elena
AU - Sevillano, Angel
AU - Merida Herrero, Evangelina
AU - Miquel Blasco Pelicano, Josep
AU - Rodas Marin, Lida Maria
AU - Quintana, Luis F.
AU - Antonieta Azancot Rivero, Maria
AU - Ramos Terrades, Natalia
AU - Garcia Carro, Clara
AU - Agraz Pamplona, Irene
AU - Salgueira Lazo, Mercedes
AU - de la Prada Alvarez, Francisco
AU - Alonso Garcia, Fabiola
AU - Adrian Aguilera Morales, Wenceslao
AU - Virxinia Pol Heres, Salia
AU - Forcen, Angel
AU - Parra Moncasi, Eduardo
AU - Medrano Villarroya, Cristina
AU - Soria Villen, Alejandro
AU - Gracia Garcia, Olga
AU - Velo Plaza, Mercedes
AU - Sánchez de la Nieta, Maria Dolores
AU - Calvo Arevalo, Marta
AU - Moreno, Antolina
AU - Cigarran Guldris, Secundino
AU - de Vicente, Manuel Pereira
AU - Munar Vila, Maria Antonia
AU - Hsu, Bang Gee
AU - Wang, Chih Hsien
AU - Chen, Cheng Hsu
AU - Yu, Tung Min
AU - Wu, Ming Ju
AU - Tsai, Shang Feng
AU - Hsu, Chia Tien
AU - Chiu, Hsien Fu
AU - Chou, Kang Ju
AU - Fang, Hua Chang
AU - Lee, Po Tsang
AU - Chen, Hsin Yu
AU - Chen, Chien Liang
AU - Huang, Chien Wei
AU - Ou, Shih Hsiang
AU - Ho, Tzung Yo
AU - Hsu, Chih Yang
AU - Chang, Ming Shan
AU - Chiu, Yen Ling
AU - Peng, Yu Sen
AU - Shu, Kai Hsiang
AU - Pan, Szu Yu
AU - Hsu, Shih Ping
AU - Yang, Ju Yeh
AU - Pai, Mei Fen
AU - Tseng, Po Yu
AU - Wu, Hon Yen
AU - Tsai, Wan Chuan
AU - Tung, Kuei Ting
AU - Chen, Hung Yuan
AU - Chen, Hung Chun
AU - Kuo, Mei Chuan
AU - Hwang, Daw Yang
AU - Chiu, Yi Wen
AU - Hung, Chi Chih
AU - Kuo, Hung Tien
AU - Tsai, Jer Chia
AU - McCafferty, Kieran
AU - Forbes, Suzanne
AU - Dasgupta, Indranil
AU - Thomas, Mark
AU - Mahdi, Amar
AU - Ajayi, Bamidele
AU - Chowdhury, Paramit
AU - Kasimatis, Theodoros
AU - Moutzouris, Dimitrios
AU - Dudreuilh, Caroline
AU - Pruthi, Rishi
AU - Mansfield, Nick
AU - Doctor, Gabriel
AU - Shah, Sapna
AU - Kon, Sui
AU - Smith, Priscilla
AU - Hamilton, Patrick
AU - Kanigicherla, Durga
AU - Ibrahim Ragy, Omar Sherin
AU - Alchi, Bassam
AU - Flossmann, Oliver
AU - Ghalli, Farid
AU - Lawman, Sarah
AU - Sinha, Smeeta
AU - Chrysochou, Constantina
AU - Chukwu, Chukwuma
AU - Maire De Bhailis, Aine
AU - Al Chalabi, Saif
AU - Hudson, Amy
AU - Gopu, Arun
AU - Wickens, Olivia
AU - Storrar, Joshua
AU - Wahba, Mona
AU - Lorde, Nathan
AU - Rony, Mohammad
AU - Griffin, Sian
AU - Latif, Farah
AU - Ali, Mohammad
AU - DaSilva, Louise
AU - Ayling-Smith, Jonathan
AU - Mahdi, Eamon
AU - Willcocks, Lisa
AU - Jones, Rachel
AU - Cheung, Chee Kay
AU - Selvaskandan, Haresh
AU - Pugh, Dan
AU - Sayer, Matthew
AU - Dhaun, Neeraj
AU - Chapman, Fiona
AU - Mark, Patrick
AU - Geddes, Colin
AU - McQuarrie, Emily
AU - Patel, Rajan
AU - Solomon, Laurence
AU - Ponnusamy, Arvind
AU - Morris, Adam
AU - Okoh, Pedro
AU - Floyd, Lauren
AU - Dhaygude, Ajay
AU - Leung, Janson
AU - Goldsmith, Christopher
AU - Pandya, Bhavna
AU - Tez, Didem
AU - Mikhail, Ashraf
AU - Brown, Karen
AU - Bucknall, Thomas
AU - Lambie, Mark
AU - Comunale, Roderick
AU - Brandon, Donald
AU - Martinez, Stacy
AU - Hall, Amanda
AU - Henderson, Amy
AU - Fearday, Aaron
AU - Douthit, Nicole
AU - Snow, Brian
AU - Silva, Arnold
AU - Sly, Cathylee
AU - Keller, Christopher
AU - Davidson, Robert
AU - Meng, Jerry
AU - Haws, Robert
AU - Kattamanchi, Siddhartha
AU - Mojarrab, Javad
AU - Pillai, Unnikrishnan
AU - Lafayette, Richard
AU - O'Shaughnessy, Michelle
AU - Kamal, Fahameedah
AU - Mehta, Kshama
AU - Baker, Bruce
AU - Ruiz, Mario
AU - Jyothinagaram, Praveena
AU - Peri, Usha
AU - Paxton, William
AU - Tumlin, James
AU - McGreal, Kerri
AU - McCarthy, Ellen
AU - Kimber, Cassandra
AU - Gautam, Archana
AU - Khalil, Kassem
AU - Nguyen, Viet
AU - Minasian, Raffi
AU - Arfaania, Dariush
AU - Daneshvari, Sam
AU - Zakari, Michel
AU - Patrikyan, Artashes
AU - Afsari, Rouzbeh
AU - Ayvazyan, Christine
AU - Fakih, Faisal
AU - Lagatta, Mark
AU - Rodriguez, Alfred
AU - Avella, Jorge Enrique Monroy
AU - Patak, Ramachandra
AU - Kadakia, Jigar
AU - Appel, Gerald
AU - Ahn, Wooin
AU - Nelson, Bradley
AU - Medina, Allyson
AU - Ahmad, Syeda
AU - Peleg, Yonatan
AU - Clement, Nisha
AU - Chiu, Ian
AU - Hendren, Elizabeth
AU - Bomback, Andrew
AU - Canetta, Pietro
AU - Spinowitz, Bruce
AU - Charytan, Chaim
AU - Parikh, Nishita
AU - Kuo, Sheng
AU - Raichoudhury, Ritesh
AU - Dobre, Mirela
AU - Negrea, Lavinia
AU - Padiyar, Aparna
AU - Jittirat, Arksarapuk
AU - Pradhan, Nishigandha
AU - Dhelaria, Ranjit
AU - Balamuthusamy, Saravanan
AU - Madhrira, Machaiah
AU - Powell, Thomas
AU - Lifland, Howard
AU - Bailey, Asha
AU - Ford Sightler, Sarah Ashley
AU - Suthar, Meera Patel
AU - Green, Heather
AU - Parikh, Samir
AU - Ayoub, Isabelle
AU - Almaani, Salem
AU - Contreras, Gabriel
AU - Fornoni, Alessia
AU - Drexler, Yelena
AU - Geara, Abdallah
AU - Sheridan, Brittany
AU - Coppock, Gaia
AU - Hogan, Jonathan
AU - Gonzalez, Carlos
AU - Bhadra, Shamik
AU - Chowdhury, Pradip
AU - Kyaw, Kay
AU - Tan, May
AU - Raakesh, Lathika
AU - Mendoza, Elder
AU - Viramontes, Veronica
AU - Chaudhry, Asghar
AU - Carbonell, Juan
AU - Gadh, Rajdeep
AU - Fernandez, Victor
AU - Kassem, Mohamad
AU - Jacob, Radu
AU - Wilder, Karen
AU - Newsome, Britt
AU - Klamm, Kathryn
AU - Suyumova, Irina
AU - Kooienga, Laura Ann
AU - Janko, Catherine
AU - Rizk, Dana
AU - Julian, Bruce
AU - Caster, Dawn
AU - Perez, Erika
AU - Garg, Gunjan
AU - Gowda, Nayan
AU - Udani, Suneel
AU - Mandayam, Sreedhar
AU - Workeneh, Biruh
AU - Assefi, Ali
AU - Greco, Barbara
AU - Germain, Michael
AU - Patel, Jusmin
AU - Quinn, Sarah
AU - Sullivan, James
AU - Glaze, Jeffrey
AU - Madonia, Phillip
AU - McMahon, Kellyn
AU - Giles, Harold
AU - Adler, Sharon
AU - Dai, Tiane
PY - 2023/5/13
Y1 - 2023/5/13
N2 - BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety.METHODS: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m 2 and ≥60 mL/min per 1·73 m 2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. FINDINGS: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups.INTERPRETATION: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan.FUNDING: Travere Therapeutics.
AB - BACKGROUND: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety.METHODS: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to <60 mL/min per 1·73 m 2 and ≥60 mL/min per 1·73 m 2) and urine protein excretion at screening (≤1·75 g/day and >1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. FINDINGS: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups.INTERPRETATION: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan.FUNDING: Travere Therapeutics.
KW - Adolescent
KW - Adult
KW - Creatinine/urine
KW - Double-Blind Method
KW - Glomerulonephritis, IGA/drug therapy
KW - Humans
KW - Irbesartan/therapeutic use
KW - Proteinuria/drug therapy
KW - Treatment Outcome
UR - https://www.mendeley.com/catalogue/249405ca-259b-368f-a182-ecc07b656d2d/
U2 - 10.1016/S0140-6736(23)00569-X
DO - 10.1016/S0140-6736(23)00569-X
M3 - Article
C2 - 37015244
SN - 0140-6736
VL - 401
SP - 1584
EP - 1594
JO - The Lancet
JF - The Lancet
IS - 10388
ER -